Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR-4 (estradiol)
- Development stage
- Preclinical
- Lead developer
- Puripharm
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
PR-4 is a topical nanoemulsion formulation of estradiol developed by Puripharm for the treatment of moderate to severe vasomotor symptoms associated with menopause. Estradiol is a naturally occurring estrogen that acts as a potent agonist of the estrogen receptors (ERα and ERβ). By binding to these receptors, it helps to supplement declining estrogen levels in menopausal women, thereby alleviating symptoms such as hot flashes and night sweats. The nanoemulsion technology is designed to enhance the skin penetration and bioavailability of estradiol, potentially allowing for lower dosing and improved safety compared to traditional topical gels or oral formulations.
- Other names
- Estradiol Topical Nanoemulsion雌二醇透皮凝胶Estradiol Transdermal Gel
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on PR-4 (estradiol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR-4 (estradiol).